Abstract Number: 0165 • ACR Convergence 2021
Shear-Wave Elastography Evaluation of Major Salivary Glands and Correlation with B-mode Findings in Patients with Primary Sjögren’s Syndrome
Background/Purpose: Salivary-gland ultrasound has recently shown to help in the diagnosis and monitoring of primary Sjögren’s syndrome (pSS)1. Shear-wave elastography (SWE) is a promising tool…Abstract Number: 0311 • ACR Convergence 2021
Ultra High‐frequency Ultrasound (UHFUS) of Labial Glands in Primary Sjögren’s Syndrome: Serological and Histological Correlations
Background/Purpose: Last‐generation ultra high‐frequency ultrasound (UHFUS) transducers are highly sensitive tools potentially able to open new avenues for the identification of imaging biomarkers. Recently UHFUS…Abstract Number: 0984 • ACR Convergence 2021
Human Papillomavirus Infection Increases Risk of Primary Sjogren’s Syndrome: A Population-based Cohort Study over a 15-year Follow-up
Background/Purpose: Viral infection has been considered as an exogeneous risk factor for primary Sjogren’s syndrome (pSS). We determined whether human papillomavirus (HPV) infection was associated…Abstract Number: 0296 • ACR Convergence 2021
The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US
Background/Purpose: Diagnosis of primary Sjögren’s syndrome (pSS) is challenging due to the disease’s phenotypic heterogeneity. pSS patients frequently experience a prolonged period between symptomatic onset…Abstract Number: 0312 • ACR Convergence 2021
Prognostic Value of Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome
Background/Purpose: In the last decade, salivary gland ultrasonography (SGUS) has appeared as a useful tool for the diagnosis of primary Sjögren’s syndrome (pSS) and for…Abstract Number: 0985 • ACR Convergence 2021
Sjӧgren’s Symptom Burden Drives Immunomodulatory Therapies but Correlates Poorly with Disease Severity Markers
Background/Purpose: Sjӧgren’s syndrome (SS) patients have lower quality of life driven by symptoms of pain, depression and fatigue. These symptoms often do not respond to…Abstract Number: 0297 • ACR Convergence 2021
Describing the Disease Burden of Primary Sjögren’s Syndrome Patients: Results from a Real-World Survey in the US
Background/Purpose: Primary Sjogren’s syndrome is a highly heterogeneous condition, with limited understanding of the burden of disease. The objective of this study was to describe…Abstract Number: 0313 • ACR Convergence 2021
Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease?
Background/Purpose: Ultrasonographically depicted morphological changes of major salivary glands (SG) have been recently correlated with the disease activity in primary Sjögren’s (pSS)1. The aim of…Abstract Number: 0986 • ACR Convergence 2021
Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease affecting excretory glands and characterized by B-cell hyperactivity. Ianalumab (VAY736) is a human monoclonal antibody to B-cell…Abstract Number: 0298 • ACR Convergence 2021
The Clinical Phenotype of Isolated Ocular and Oral Dryness in Sjogren Syndrome, Fulfilling the 2016 ACR-EULAR Classification Criteria
Background/Purpose: Dry mouth and eyes are the main clinical features of Sjögren’s syndrome (SS), although a minority of patients present without sicca manifestations and isolated…Abstract Number: 0314 • ACR Convergence 2021
PROMIS Provides a Broad Overview of Health-Related Quality of Life in the Evaluation of Sjogren’s Syndrome
Background/Purpose: Sjogren’s Syndrome (SS) is a systemic autoimmune disease that has considerable impact on health-related quality of life (HRQL). The European League Against Rheumatism (EULAR)…Abstract Number: 0987 • ACR Convergence 2021
Rituximab Prevents the Progression of B-cell Driven Inflammatory Infiltrate in the Minor Salivary Glands of Primary Sjogren’s Syndrome by Downregulating Immunological Pathways Key in Ectopic Germinal Centre Organization: Results from the TRACTISS Trial
Background/Purpose: The pathogenic role of B-cells in primary Sjögren’s Syndrome (pSS) is well established and B cell abnormalities are hallmarks of the disease. Because of…Abstract Number: 0299 • ACR Convergence 2021
Sex Hormones and Risk of Sjögren’s Syndrome: Hypothesis Generating Findings Implicating Androgen and Estrogen Ratios
Background/Purpose: Sjӧgren’s syndrome (SS) is the most female predominant systemic autoimmune disease, with peak onset around perimenopause. Estrogen appears to protect against SS, but prior…Abstract Number: 0315 • ACR Convergence 2021
Sjögren’s Syndrome Symptom Diary (SSSD) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) as Assessments of Symptoms in Sjögren’s Syndrome: A Qualitative Exploration of Content Validity and Meaningful Change
Background/Purpose: The aim of this study was to gain qualitative patient feedback on the appropriateness of two Patient Reported Outcome (PRO) measures as assessments of…Abstract Number: 1440 • ACR Convergence 2021
Targeting Endogenous Mesenchymal Stromal Cell Response to Interferong in Sjӧgren’s Syndrome
Background/Purpose: Sjӧgren’s syndrome (SS) is a systemic autoimmune disease that is associated with a lymphoma risk 14-fold that of the general population. Greater focal lymphocytic…
ACR Meeting Abstracts